We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Spectral Karyotyping Detects Chromosome Damage Linked to Smoking and Lung Cancer

By Biotechdaily staff writers
Posted on 11 Sep 2007
Spectral karyotyping (SKY) detects chromosome damage in bronchial cells of smokers and patients with lung cancer.

Lung cancer is the leading cause of cancer deaths in the United States and kills more people than the next three most common cancers--colon, breast, and prostate--combined. More...
Smoking is the primary risk factor for lung cancer but a number of lung cancer patients have never smoked. Quitting smoking only gradually reduces the risk of lung cancer because much of the genetic damage done by tobacco is irreversible.

The genetic changes that accompany lung cancer are not random, but are associated with specific chromosomal instabilities that may be indicative of future carcinomas. Marileila Varella-Garcia, M.D., and colleagues of the University of Colorado Health Sciences Center (UCHSC; Denver, CO, USA) used SKY to examine the bronchial epithelium (BE) of 71 subjects--14 patients with lung cancer, 43 smokers at high risk for developing lung cancer, and 14 healthy nonsmokers--in the hope of identifying underlying genetic changes that might be hallmarks for cancer. They found a marked difference between the chromosomal abnormality index (CAI) of never-smokers and that of high-risk smokers and patients with lung cancer.

"There's a tremendous amount of chromosomal damage in smokers who don't yet have cancer,” said Dr. Wilbur Franklin, professor of pathology at the University of Colorado Health Sciences Center. "Chromosomal abnormalities were observed in 82% of high-risk smokers and in all patients with carcinoma, regardless of their self-reported tobacco exposure.” Patients with cancer and high-risk smokers had nearly 23 and 15 times more chromosomal abnormalities, respectively, than never-smokers.

The study, which could pave the way toward screening people at risk for lung cancer for genetic changes that foreshadow malignancies, appeared in the September 1, 2007, issue of the American Journal of Respiratory and Critical Care Medicine.


Related Links:
University of Colorado Health Sciences Center

New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
POC Immunoassay Analyzer
Procise DX
New
Automated Urinalysis Solution
UN-9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Plasma pTau217 testing can predict future amyloid accumulation and cognitive decline in cognitively healthy older adults (photo courtesy of Shutterstock)

Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms

Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more

Industry

view channel
Image: The GenoPredict assay from Predicta Biosciences is available to Tempus Life Sciences partners to support exploratory research and clinical development programs (photo courtesy of Shutterstock)

Partnership Expands Ultrasensitive WGS Assay for for Hematologic Malignancies and MRD Monitoring

Tempus AI and Predicta Biosciences announced the commercial expansion of a co-branded whole‑genome sequencing assay GenoPredicta, which is intended for comprehensive genomic characterization of hematologic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.